Cover |
Oct. 08, 2020 |
---|---|
Cover [Abstract] | |
Document Type | 8-K/A |
Amendment Flag | true |
Amendment Description | On October 8, 2020, Corbus Pharmaceuticals Holdings, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Form 8-K”) to report the departure of Robert Discordia as the Company’s Chief Operating Officer. The Company is filing this amendment to the Original Form 8-K to disclose the terms of the Separation and Release Agreement by and between Mr. Discordia and the Company after Mr. Discordia’s resignation as the Company’s Chief Operating Officer to pursue other interests. No other modifications have been made to the Original Form 8-K. |
Document Period End Date | Oct. 08, 2020 |
Entity File Number | 001-37348 |
Entity Registrant Name | CORBUS PHARMACEUTICALS HOLDINGS, INC. |
Entity Central Index Key | 0001595097 |
Entity Tax Identification Number | 46-4348039 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 500 River Ridge Drive |
Entity Address, City or Town | Norwood |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02062 |
City Area Code | (617) |
Local Phone Number | 963-0100 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock |
Trading Symbol | CRBP |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Entity Information, Former Legal or Registered Name | Not Applicable |